Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

88
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
88
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

56
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
56

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Inhibition of HBV gene expression by antisense oligonucleotides using galactosylated poly (L-lysine) as a hepatotropic carrier].

Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology·2001
Same author

[Chemical characteristics of fresh snow in Mount Everest Region].

Huan jing ke xue= Huanjing kexue·2001
Same author

[Comparison of specific immune responses to duck hepatitis B virus in infected, immune, and uninfected ducks].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2001
Same author

[Influence of electroporation on the biological activities of primary rat hepatocytes].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2001
Same author

Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen.

Journal of acquired immune deficiency syndromes (1999)·2001
Same author

A new approach to 4-alkylthio-1,3-dithiole-2-thione: an unusual reaction of a zinc complex of 1,3-dithole-2-thione-4,5-dithiolate.

Organic letters·2001

Related Experiment Video

Updated: Mar 21, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.3K

Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based

Y Xu1, Y F Li1, D Zhang1

  • 1Merck Sharp & Dohme Corp, Kenilworth, New Jersey, USA.

Clinical and Translational Science
|May 13, 2016
PubMed
Summary

This study sets pharmacokinetic targets for new HIV-1 drugs by analyzing viral suppression data. These targets will guide the development of nonnucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors (InSTIs).

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.4K
A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

16.3K

Related Experiment Videos

Last Updated: Mar 21, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.3K
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.4K
A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

16.3K

Area of Science:

  • Pharmacology
  • Virology
  • Drug Development

Background:

  • Antiretroviral therapy is crucial for managing HIV-1 infection.
  • Optimizing drug exposure and potency is key to effective HIV-1 treatment.
  • Pharmacokinetic (PK) targets inform the development of new antiretroviral drugs.

Purpose of the Study:

  • To establish pharmacokinetic targets for nonnucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors (InSTIs).
  • To guide the preclinical development and early clinical trial design of novel HIV-1 therapies.

Main Methods:

  • Model-based meta-analysis of viral suppression data from short-term monotherapy studies in HIV-1-infected, treatment-naïve patients.
  • Development of class-specific models linking viral load kinetics to potency-normalized steady-state trough plasma concentrations.
  • Integration of models with literature data on long-term combination therapy efficacy.

Main Results:

  • Established class-specific models relating viral suppression to drug exposure and in vitro potency.
  • Derived steady-state trough concentration targets: 6.17-fold above potency for NNRTIs and 2.15-fold for InSTIs.
  • Demonstrated the utility of models and targets for guiding antiretroviral drug development.

Conclusions:

  • The developed models and PK targets provide a framework for selecting compounds in preclinical development.
  • These findings will aid in predicting the dose-response of new antiretrovirals, informing early clinical trial design.
  • Optimized PK targets are essential for the successful development of effective NNRTIs and InSTIs for HIV-1 treatment.